Write a comment
  • Webinars
  • Emerging therapeutic targets for migraine

Emerging therapeutic targets for migraine



December 09, 2021
Thursday, December 9, 2021 3:00 PM [London]
  • Prof Amynha Pradhan
CPD/CME Credits

Prof Amynha Pradhan | Department of Psychiatry, University of Illinois at Chicago, USA

Migraine is the third most prevalent disease worldwide and is estimated to affect upwards of 14% of the population. Our lab has used novel preclinical models to identify the delta opioid receptor (DOR) as a therapeutic target for multiple headache disorders, including migraine. We have also investigated the relationship between DOR with the pro-migraine peptide, CGRP. There is regional variation between the co-expression of DOR with CGRP or its receptor in the trigeminal complex. This work indicates that DOR agonists can moderate both CGRP release and signaling, thus regulating pro-migraine effects at two different levels. Recent work in our lab has also explored how cytoarchitectural changes in pain processing regions are critical for the maintenance of the chronic migraine state. We show that there is decreased neuronal complexity in two different models of migraine, and that restoration of tubulin dynamics, directly by HDAC6 inhibitor or indirectly by CGRP receptor antagonist, can inhibit migraine-associated symptoms. These studies provide fundamental information on how cytoskeletal dynamics are altered in chronic migraine, and form the basis for the development of HDAC6 inhibitors for headache treatment.

Comments and documents uploaded on our website are often checked to make sure they stick to ICNA & ICNApedia rules for commenting and uploading. And if they don't, they're removed.

Say something here...
Log in with ( Sign Up ? )
or post as a guest
Loading comment... The comment will be refreshed after 00:00.

Be the first to comment.

A Child Without a Shadow: A Memoir of a Holocaust Survivor and a World Famous Doctor

November 16, 2021 News ICNA
A Child without A Shadow The moving story of Professor Shaul Harel’s life from darkness to light, from Holocaust survivor to world expert in pediatric neurology and child development.

New treatment of Fukuyama congenital muscular dystrophy

October 10, 2021 News ICNA
Scientists rescue Fukuyama congenital muscular dystrophy-related brain defects in a new organoid model developed using stem cells from affected patients Fukuyama congenital muscular dystrophy (FCMD) is a severe genetic neuromuscular disorder affecting the…
Maha Zaki

Zaki syndrome: Researchers identify unknown childhood genetic disorder

October 10, 2021 News ICNA
Maha S. Zaki, MD, PhDA study published in The New England Journal of Medicine details how researchers discovered a previously unknown genetic disorder that affects prenatal development in children and identified a potential cure. Through a worldwide…
cns icna pkt neuromuscular course min

The CNS-ICNA Pediatric Neurology Virtual Course

September 23, 2021 News ICNA
The CNS-ICNA supported Pediatric Neurology virtual course spanning over the next 4 months, mainly for Asia region is being hosted by Lahore, Pakistan. The upcoming Neuromuscular workshop is on Sep 25, 2021. Saturday 5-8 PM PKT. EMG/ NCS /EP Hands-on workshop…
mike johnston

Kennedy Krieger Institute announces the new Michael V. Johnston Center for Developmental Neuroscience

September 23, 2021 News ICNA
Kennedy Krieger Institute celebrates Dr. Michael V. Johnston’s career, as they announce the new Michael V. Johnston Center for Developmental Neuroscience at Kennedy Krieger Institute. Dr. Johnston is a role model for many physicians and scientists across the…